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Registry participants ðN ¼ 2418Þ and results were collated by AATD phenotype.
Participants with PiZZ deficiency were compared to PiMZ and other phenotypes by
nonparametric statistics. Responses were collected from 757 participants (31%).
Overall 44.6% ðN ¼ 338Þ reported MD diagnosed asthma. Wheezing was reported in
76% with respiratory infections, activity and exposure to dusts, fumes, and allergens
as common triggers. Across the three groups reported asthma with a history of
allergies was reported from 20% to 25%. Wheezing symptoms were significantly less
common in the PiMZ group compared with other groups. Of those reporting asthma,
83% of the PiZZ group ðn ¼ 192Þ also reported another chronic obstructive pulmonary
disease (COPD) diagnosis compared to 48% of the PiMZ group ðn ¼ 24Þ. Asthma as the
only reported diagnosis was three times more prevalent in the PiMZ group compared
with the PiZZ group. Although asthma diagnosis is imprecise in the presence of COPD,
the high prevalence of wheezing to allergen and irritant exposures with symptoms of
atopy suggests that asthma is common in AATD but usually associated with COPD.
Those with AATD who are susceptible to asthma require allergy evaluation and
aggressive anti-inflammatory strategies as part of their management.
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Alpha-1 antitrypsin deficiency (AATD) is a hetero-
geneous disorder with a broad spectrum of AAT
phenotypes which impart a varying susceptibility to
obstructive lung disease and emphysema. Protease
inhibitor (Pi) Z is the commonest allele for the
homozygous (PiZZ) severe deficiency that signifi-
cantly increases the susceptibility to lung function
loss and emphysema in smokers and nonsmokers.1
PiMZ, the heterozygous condition, carries only a
slightly higher independent risk of obstructive lung
disease.1 The inheritance of an intermediate
deficiency state such as PiSZ leads to intermediate
susceptibility. Along with the enhanced suscept-
ibility to the development of chronic obstructive
pulmonary disease (COPD) may also be an enhanced
susceptibility to asthma.
Asthma is the most common respiratory diagnosis
in patients with AATD prior to the diagnosis of
AATD.2 In COPD bronchial hyperresponsiveness is
associated with a more rapid lung function decline3
and worse than expected survival.4,5 This also
appears to be true in AATD.6,7 Furthermore, the
presence of asthma increases FEV1 decline,
8,9 and
is a likely independent risk factor for the develop-
ment of COPD.10,11 Atopy which predisposes to
asthma has also been reported to be more
prevalent in those with AATD.12,13
Given the potential adverse effects of asthma
and atopy in AATD, this study was undertaken to
establish the prevalence of these in AATD and to
determine the relationship between asthma and
COPD in groups with varying severity of AATD.Methods
The Alpha-1 Foundation Research Registry is a
confidential research database established in 1997
by the Alpha-1 Foundation to enroll individuals
with AATD and carriers. The Registry is located
at the University of South Carolina in Charleston.
The Registry is open to those with diagnosed
AATD who are invited by mail to join the
Registry by submitting an enrollment question-
naire. Enrollment occurs from screening and
education programs or through referral from
physicians or family members. All Registry partici-
pants sign a consent form that was returned to the
Registry Center. Over 94% of participants reside in
the United States.
The current study consisted of a questionnaire
piloted by a small number of AATD patients then
mailed to every member of the Registry ðN ¼ 2431Þon 1/15/2004. The questionnaire was based on
the ATS DLD 78 used in the NHLBI Registry.14
Additional questions requested a physician
diagnosis, medication history and effectiveness,
and a prior history of asthma and allergy. The
questions were constructed as commonly
asked in clinical practice. Self-reported asthma
diagnosis was based on the question ‘‘Have
you ever been diagnosed by a doctor with asthma?’’
Self-reported diagnoses of COPD, Emphysema,
Chronic bronchitis and Bronchiectasis were
made with positive responses to similarly
phrased questions. In addition, the diagnosis of
chronic bronchitis was made in response to
‘‘Do you bring up phlegm on most days for 3
consecutive months or more during the year?’’
and ‘‘How many years have you had trouble
with cough and phlegm?’’ Questions on wheezing
were phrased for example as ‘‘Do you get attacks of
wheezing and whistling in the chest?’’ Further
questions explored precipitating factors and
responses to bronchodilators. For questions on
allergy participants were asked to enter what they
thought they were allergic to and what allergies
had been diagnosed by a physician. Questionnaire
return was accepted until 3/31/04 when data
analysis began. Up to three follow-up telephone
calls were made to individuals who reported not
knowing their phenotype.
The denominator in percentage calculations was
adjusted based on the number of responses to a
particular question. Reported percentages were
rounded to the nearest whole number. Statistics
were performed in SAS (Cary, NC). Different
permutations of a clinical definition of asthma
were used for intermittently wheezing individuals.
These were physician diagnosed asthma with or
without concurrent pulmonary diagnoses of COPD,
emphysema, chronic bronchitis, and bronchiecta-
sis. The cohort was grouped into severe PiZZ AATD,
PiMZ carriers with a mildly reduced AAT and a third
‘‘others’’ group combining PiMS, PiSS, PiSZ and
other rare AAT phenotypes with those who did not
know their phenotype. The normal approximation
to the binomial test and Pearson’s w2-test was used
for the comparison of categorical variables in the
current cohort with historical data in the Alpha-1
Registry population. For comparisons within the
current cohort, a w2-test was applied to categorical
variables and ANOVA for continuous variables. P
values o0.05 were accepted as significant. For
small sample sizes the Wilcoxon Rank Sum test was
applied for testing mean differences in continuous
variables and the Fisher’s Exact test for testing the
association between phenotype and each catego-
rical variable.
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The questionnaire was returned by 757 individuals
(31%). Differences between the cohort returning
and not returning the questionnaire are shown in
Table 1. The proportions of different phenotypes
are significantly different in the current cohort
compared with the Registry with significantly less
unknown phenotypes. Mean ages for the three
groups were 55713 years, 48717 years and 52717
years, respectively. There were 265 nonsmokers
(35%), 459 ex-smokers (61%) and 30 current
smokers (4%). The frequency distribution of smok-
ing status in the survey cohort was not significantly
different from the Registry cohort.
A diagnosis of COPD was reported in 42%
ðN ¼ 319Þ, emphysema in 57%, chronic bronchitis
in 28%, and bronchiectasis in 10%. In PiZZ
participants COPD was diagnosed in 51%
and emphysema in 71%, in PiMZ 20% and 21%,Table 1 Characteristics of study participants compared
Registry total (N ¼ 2431)
Phenotype
PiZZ 1337 (55%)
PiMZ 459 (19%)
PiSZy 84 (4%)
Other phenotypesy 74 (3%)
Not knowny 477 (20%)
% Reporting asthma 842 (35%)
Nonsmokers 867 (36%)
The normal approximation to the binomial test was applied.
yCategories combined into a single ‘‘other’’ group.
zPearson’s w2-test was used.
yNS ¼ Not significant at a level of 0.05.
Table 2 Affirmative responses to questions on wheezing
Characteristics of wheezing PiZZ
Wheezing in past 12 months? 67%
Wheezing days in the last 12 months?
(mean7SD)
717110
Wheezing with a cold? 66%
Wheezing apart from a cold? 56%
Wheeze most days? 16%
Wheezing attacks disturb sleep? 18%
Wheezing during or after activity that
causes shortness of breath?
56%
Wheezing after dusts, fumes, strong
smells?
52%
Wheezing after contact with allergy? 33%
w2-tests were applied for categorical variables and ANOVA forrespectively, and in 39% and 54%, respectively, in
‘‘others’’ group.Prevalence of self-reported asthma
A physician diagnosis of asthma was reported in 45%
ðN ¼ 338Þ of the cohort. An asthma diagnosis
occurred in 50% of PiZZ individuals, 31% of PiMZ
individuals and 42% of others. The mean age for
asthma diagnosis was 38718 years in PiZZ, 30718
years in PiMZ and 35719 years in ‘‘others’’ group.
‘‘Ever wheezing or whistling in the last 12
months’’ was reported in 76%. Ever wheezing was
reported in 81% of PiZZ, 61% of PiMZ and 79% of
other phenotypes ðPo0:0001Þ.
Except for allergy contact the prevalence of
wheezing symptoms are significantly different
between phenotypes (Table 2). Self-reported fac-
tors associated with asthma attacks were reportedto registry participants.
Study cohort (N ¼ 757) P-value
o0.0001
458 (61%)
164 (22%)
32 (4%)
11 (1%)
92 (12%)
338 (44%) o0.0001z
265 (35%) NSy
symptoms by AATD phenotype.
PiMZ Other
phenotypes
P-value
41% 62% o0.0001
56795 627100 NS
46% 70% o0.0001
39% 57% 0.0004
9% 19% 0.035
15% 24% NS
40% 58% 0.0015
33% 53% o0.0001
31% 33% NS
the continuous variable.
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emotions and allergies.Asthma symptoms and diagnosis as related to
smoking status
In 265 nonsmokers 62% reported ever-wheezing
whereas in 489 either ex-smokers or current
smokers, 84% reported ever-wheezing (Po0:001
by w2). Of nonsmokers, 37% reported asthma
compared with 49% in current smokers or ex-
smokers. For reported asthma in the PiZZ group
46% were nonsmokers vs. 52% were ex- and current
smokers, in the PiMZ group 26% nonsmokers vs. 36%
ex- and current smokers reported asthma and in the
‘‘others’’ group 33% vs. 46%, respectively. The
percent of nonsmokers was significantly greater in
the PiMZ group than in the other groups (Table 3).
Current smokers or ex-smokers with a physician
diagnosis of asthma were more likely to report
both emphysema and chronic bronchitis than in
nonsmokers (41% vs.18%, respectively). Isolated
self-reported asthma was more common in non-
smokers, 48%, than in current smokers or ex-
smokers, 14%. The frequency distribution among
different asthma conditions (never wheezing with
isolated asthma, wheezing with isolated asthma,
wheezing with asthma and other diseases) isTable 3 Past medical history of wheezing attacks, asthm
Past history PiZZ
Age asthma diagnosed, years (Mean7SD) 39716
Age at 1st attack, years (Mean7SD) 32715
2 or more attacks? 92%
Inhaler use to treat attacks? 87%
Relief of attack within 30min? 80%
Are wheezing attacks still present? 69%
Age if stopped, years (Mean7SD) 46714
Family with asthma? 56%
Nonsmokers 26%
w2-tests or Fisher Exact tests were applied for categorical var
yWilcoxon Rank Sums test.
Table 4 Affirmative responses to questions related to a
Variable PiZZ (%) Pi
Do you have allergies? 58 63
Did an MD tell you? 35 45
Do you take meds for allergies? 27 33
Have you received allergy shots? 14 18
aChi-square tests were applied for categorical variables and ANsignificantly different between nonsmokers and
smokers (w2 P-valueo0.0001).
Past history of asthma
For asthma attacks that had occurred greater than
1 year prior to completion of the questionnaire, in
response to the question ‘‘In the past, have you
ever had an attack of wheezing that has made you
feel short of breath’’, 45% of PiZZ, 38% of PiMZ and
41% of other phenotypes answered affirmatively.
Table 3 shows details of symptoms and family
history in the 323 participants answering affirma-
tively according to phenotype. It is notable that the
time from the first wheezing attack to diagnosis is
reported as 7 years in the PiZZ group.
History of atopy
As atopy is a risk factor for asthma, respondents
were asked a series of questions on the presence,
type and treatment of allergies (Table 4).
In order of frequency, dust and dust mites,
pollen, animals and molds were mentioned as
allergens. In general, specific allergens causing
respiratory symptoms were reported more fre-
quently by patients than were diagnosed by
physicians.a and smoking by AATD phenotype.
PiMZ Other phenotypes P-value
28718 33719 0.0017
26716 31718 NS
92% 93% NS
82% 84% NS
73% 82% NS
60% 84% 0.018
35716 51712 NSy
76% 67% 0.014
50% 20% 0.0003
iables and ANOVA for continuous variables.
llergy by AATD phenotype.
MZ (%) Other phenotypes
(%)
P-valuea
53 NS
34 NS
30 NS
14 NS
OVA for continuous variables.
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Table 5 Univariate comparisons of affirmative responses to questions about asthma and wheezing attacks by
augmentation usage in subjects with the PiZZ phenotype (Total 443 subjects).
Variable No augmentation (N ¼ 136) Augmentation (N ¼ 307) P-valuez
Cases %y Cases %
Diagnosed asthma by MD 60 44 166 54 0.05
Ever wheeze 94 69 268 87 o0.0001
Wheezing in past 12 months 73 54 228 74 o0.0001
Wheezing with cold 73 54 223 73 o0.0001
Wheezing after allergy contact 38 28 106 34 NS
Attacks immediately after activity 63 46 186 61 0.005
Attacks from dust/fumes/strong smells 59 43 173 56 0.01
Number of respondents with affirmative responses to the variable.
yPercentage of cases over nonmissing responses.
zw2-tests were applied.
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diagnosed asthma self-reporting allergies was 92%
for PiZZ, 94% for PiMZ and 96% for ‘‘others’’. In
contrast, within each group, the percentage re-
porting physician diagnosed allergy and asthma was
less: 49% of PiZZ, 64% of PiMZ and 58% of ‘‘others’’.Medication therapy for asthma
The time to effective relief of bronchospasm by
bronchodilator therapy was not significantly differ-
ent between those reporting asthma compared
with those reporting COPD. In the PiZZ group, for
those reporting emphysema the mean time for
bronchodilator response was 8.078min compared
to 7.676min for those reporting asthma and
14.7757min for those reporting both asthma and
emphysema.
In participants with physician diagnosed asthma,
34% of PiZZ, 10% of PiMZ and 25% of ‘‘others’’
reported that augmentation therapy for AATD
helped their asthma symptoms. Table 5 compares
augmentation use in PiZZ and PiMZ groups as
related to asthma diagnosis and wheezing symp-
toms. The percentage of current and ex-smokers
was significantly greater in the augmentation group
compared to the group without augmentation use
ðPo0:001Þ (data not shown).Overlap of reported asthma and COPD
A nonproportional Venn diagram Fig. 1A illustrates
the diagnostic overlap in the cohort. Forty-six
percent of respondents reporting ever wheezing
did not report a physician diagnosis of asthma. In
participants reporting asthma, 27% did not report
an additional diagnosis of emphysema and orchronic bronchitis, 34% reported all three condi-
tions. Of interest 7% reporting asthma did not
report wheezing whereas 19% reporting wheezing
did not report asthma, chronic bronchitis or
emphysema.
Figure 1B indicates that in the PiZZ group 83% of
those reporting asthma also reported another COPD
diagnosis. In contrast, of the PiMZ group 48% of
those reporting asthma reported another COPD
diagnosis (Fig. 1C). In this group, 23% indicated that
they had ever wheezed but did not report any COPD
diagnosis compared to 12% in the PiZZ group.
Comparison of asthma only and ever wheezing
indicates a significantly greater prevalence in the
PiMZ compared to the PiZZ group (Pearson w2-test
Po0:001). The estimated ratio of prevalence was
3.2 (95% confidence limit 1.8–5.7).
In asthma diagnosed by a physician and self-
reported but without COPD, the mean age of
asthma diagnosis was significantly less in the PiMZ
group (26715, N ¼ 20) compared to the PiZZ group
(47716, N ¼ 23) ðP ¼ 0:003Þ but other self-re-
ported variables were not significantly different.Discussion
This study was designed to estimate the prevalence
of asthma and allergy in a large cohort with AATD
participating in the Alpha-1 Foundation Research
Registry. Asthma is a risk factor for an accelerated
decline in FEV1.
3,6,7 In a 20-year follow-up study
from Tucson,10 physician diagnosed asthma is a risk
factor for COPD with the length of time to asthma
diagnosis an additional independent risk factor. To
prevent this increased susceptibility to the loss of
lung function over and above that induced by AATD
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AATD is paramount. Unfortunately, results from this
study suggest that the time from symptom devel-
opment to the diagnosis of asthma may be delayed
in severe AATD (Table 3).
The results indicate that 44% of participants
report a physician diagnosis of asthma. The currentCHRONIC
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(A)
(B)
(C)estimate is higher than the previously reported
21%6 because of the likely higher questionnaire
return rates from individuals with asthma inter-
ested in answering questions about asthma. Also
ATS/ERS guidelines1 recommend AATD testing on
those with asthma that is not completely reversible
increasing the potential for recruitment bias in
asthmatics. The findings are however supported by
prior observations12,13 which suggest an association
between asthma in severe AATD. In this study,
approximately one-third of PiMZ subjects report a
physician diagnosis of asthma and over 44% with
physician diagnosed allergies. These findings add
support to the controversial association between
the PiMZ phenotype asthma and atopy.1
In COPD, wheezing is common and spirometric
bronchodilator responsiveness, a characteristic of
asthma, is more prevalent as % FEV1 declines.
9,15 In
this cohort, current smokers or ex-smokers with a
physician diagnosis of asthma are more likely to be
also diagnosed with emphysema and/or chronic
bronchitis than nonsmokers (41% vs.18%, respec-
tively). Asthma diagnosis and asthma symptoms are
reported significantly more often in PiZZ partici-
pants receiving augmentation therapy in whom
COPD tends to be more severe.14 Therefore, the
spectrum of airflow obstruction in AATD includes
asthma symptoms but the diagnosis as the cause of
symptoms is likely to be imprecise because of
overlapping features of asthma and COPD.
Certain aspects of the medical history may
support a diagnosis of asthma in the presence of
COPD. Asthma is associated with defined triggers of
attacks such as viral infections, dusts, fumes and
allergens and a positive family history. In this
cohort, wheezing attacks appear to be associated
with a COPD diagnosis especially in the PiZZ group.
Triggered wheezing attacks are generally less
frequent in PiMZ individuals, a group with less
COPD and emphysema, but still occur in up to 46%
(Table 2). It is also notable that a family history of
asthma was reported commonly in the three groupsFigure 1 (A) shows a nonproportional Venn diagram for
the Registry participants to indicate the proportion of
subjects reporting one or more COPD conditions. The box
represents the total cases. The diagrams are further
subdivided according to whether or not ever wheezing
was reported in the questionnaire. The three circles
within represent chronic bronchitis, emphysema and
asthma. The numbers in each area indicate the number
of participants in each category. Numbers in parentheses
show the percentage of participants reporting asthma in
each category. (B) As above but for participants with the
PiZZ phenotype. (C) As above but for participants with
the PiMZ phenotype.
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due to the overlap of COPD with asthma in families
with AATD.
Atopy confers a genetic predisposition to asthma16
and this study supports a previous study,13 where
positive skin reactions to common aeroallergens
occurred in 48% in a group with severe AATD and
COPD compared with 28% in COPD controls. In atopy,
a reduced level of AAT may also enhance the
severity of airway hyperresponsiveness.17 The diag-
nosis of allergy is often made by patients and
physicians without confirmatory testing and may not
be accurate. For example in participants with a
physician diagnosis of asthma, self-reported aller-
gies were almost universally present in the three
groups whereas physician diagnosed allergy and
asthma was less (49–64%) but still occurred com-
monly. Allergen-induced wheezing was reported in
about a third and appeared independent of AATD
severity (Table 2). Immunotherapy may be offered
as a treatment option but only a small percent
reporting allergen sensitivity received immunother-
apy. Therefore, an allergy evaluation, with avoid-
ance of triggers, should be an important part of the
management of those with AATD who describe
wheezing attacks triggered by allergen exposure.
A comparison of reported asthma was made
between PiMZ and PiZZ groups who did not report
an additional diagnosis of COPD. First, the pre-
valence of reported asthma in the absence of COPD
was 3 times greater in the PiMZ group than in the
severe AATD group. This finding is not unexpected
as COPD is much less common in the heterozygous
group. Second, the age of reported asthma diag-
nosis in the PiMZ group is similar to previously
reported large studies18 and significantly less than
in this PiZZ subset. The younger age in the PiMZ
group suggests the presence of asthma without
COPD. Asthma alone also occurs in those with the
severe deficiency before the development of COPD.
In a prospective cohort study,19 an asthma pre-
valence of 15% was reported in 129 PiZZ subjects
with normal lung function followed for the first 22
years. In most with severe AATD, however, asthma
is diagnosed at a later age when COPD has already
developed.
The reported data are subject to physician and
participant bias. For example 13% of those never
reporting a wheezing attack report a physician
diagnosis of asthma and 6–8% of participants are
diagnosed with asthma but never wheeze. Also
15–23% report ever wheezing without reporting any
physician diagnosis. Lack of an objective measure-
ment for asthma leads to bias in diagnosis20 and
lack of patient reporting may hamper efforts to
identify those with AATD early in their disease.Asthma is the most common respiratory diagnosis in
patients with AATD prior to the diagnosis of AATD.2
A major finding in this study is the high
prevalence of self-reported wheezing with allergen
and irritant exposures. Physician diagnosed asthma
and allergies are also reported commonly in AATD.
Asthma is difficult if not impossible to distinguish
clinically from COPD in those with established
airflow obstruction. Given the overlap between
asthma and COPD in this population and the
potential impact of asthma on FEV1 loss, evaluation
of the wheezy patient with AATD should include
allergy testing and aggressive treatment to reduce
bronchial hyperresponsiveness.Acknowledgment
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